ES2530428T3 - Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos - Google Patents

Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos Download PDF

Info

Publication number
ES2530428T3
ES2530428T3 ES07837788T ES07837788T ES2530428T3 ES 2530428 T3 ES2530428 T3 ES 2530428T3 ES 07837788 T ES07837788 T ES 07837788T ES 07837788 T ES07837788 T ES 07837788T ES 2530428 T3 ES2530428 T3 ES 2530428T3
Authority
ES
Spain
Prior art keywords
antibody
treatment
compositions
methods
mediated neuropathies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07837788T
Other languages
English (en)
Inventor
Susan Halstead
Hugh Willison
Russell Rother
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2530428T3 publication Critical patent/ES2530428T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un anticuerpo para uso en el tratamiento de síndrome de Guillain-Barré en un mamífero, en el que dicho anticuerpo se une a: (i) el componente del complemento C5 e inhibe la escisión de C5 en fragmentos C5a y C5b; o (ii) C5b, en el que dicho anticuerpo inhibe la formación del complejo de ataque a membrana.
ES07837788T 2006-09-05 2007-09-05 Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos Active ES2530428T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84229606P 2006-09-05 2006-09-05
PCT/US2007/019416 WO2008030505A2 (en) 2006-09-05 2007-09-05 Methods and compositions for the treatment of antibody mediated neuropathies

Publications (1)

Publication Number Publication Date
ES2530428T3 true ES2530428T3 (es) 2015-03-02

Family

ID=39157834

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07837788T Active ES2530428T3 (es) 2006-09-05 2007-09-05 Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos
ES11005615.7T Active ES2616204T3 (es) 2006-09-05 2007-09-05 Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11005615.7T Active ES2616204T3 (es) 2006-09-05 2007-09-05 Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos

Country Status (16)

Country Link
US (1) US9388235B2 (es)
EP (4) EP2913342A1 (es)
JP (2) JP5695317B2 (es)
KR (1) KR101503540B1 (es)
AU (1) AU2007293013B2 (es)
BR (1) BRPI0715869A2 (es)
CA (1) CA2662480C (es)
DK (1) DK2061810T3 (es)
ES (2) ES2530428T3 (es)
IL (1) IL197148A (es)
MX (1) MX2009002426A (es)
NZ (1) NZ575018A (es)
PL (1) PL2061810T3 (es)
PT (1) PT2061810E (es)
SI (1) SI2061810T1 (es)
WO (1) WO2008030505A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
CN102203604B (zh) * 2008-10-21 2014-09-10 托马斯·M·东德林格 用于防止组织样品中伪像的方法和组合物
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
WO2014186622A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
CA2940579A1 (en) 2014-03-13 2015-09-17 Universitaet Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
ES3013108T3 (en) 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
CN107278206B (zh) * 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
CN115260310B (zh) 2015-11-24 2025-02-25 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
US20220133841A1 (en) * 2018-10-22 2022-05-05 Ra Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
TW202404632A (zh) * 2022-04-04 2024-02-01 瑞士商赫孚孟拉羅股份公司 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2097825A1 (en) 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ES2252746T3 (es) 1994-09-23 2006-05-16 Alexion Pharmaceuticals, Inc. Procedimientos para el tratamiento de la enfermedad inflamatoria articular.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1999037149A1 (en) * 1998-01-27 1999-07-29 Brigham & Women's Hospital Methods of treating cytotoxic damage
US6492403B1 (en) * 1999-02-09 2002-12-10 3-Dimensional Pharmaceuticals, Inc. Methods of treating C1s-mediated diseases and conditions and compositions thereof
EP2113516B1 (en) * 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2457461C (en) 2001-08-17 2013-12-24 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
EP1589996A4 (en) 2003-01-30 2009-01-21 Medimmune Inc ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2005002513A2 (en) 2003-06-16 2005-01-13 The Brigham And Women's Hospital, Inc. C1q complement inhibitors and methods of use thereof
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
AU2007224250B2 (en) 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity

Also Published As

Publication number Publication date
DK2061810T3 (en) 2015-02-16
SI2061810T1 (sl) 2015-04-30
PL2061810T3 (pl) 2015-05-29
EP2061810A2 (en) 2009-05-27
JP5695317B2 (ja) 2015-04-01
KR20090051063A (ko) 2009-05-20
AU2007293013B2 (en) 2013-06-27
KR101503540B1 (ko) 2015-03-17
PT2061810E (pt) 2015-02-05
MX2009002426A (es) 2009-03-20
JP2010502708A (ja) 2010-01-28
IL197148A0 (en) 2011-08-01
EP2061810B1 (en) 2014-11-12
AU2007293013A1 (en) 2008-03-13
US20100143343A1 (en) 2010-06-10
US9388235B2 (en) 2016-07-12
NZ575018A (en) 2012-04-27
JP2014240438A (ja) 2014-12-25
EP2380907B1 (en) 2016-11-30
HK1126793A1 (en) 2009-09-11
EP3199549A1 (en) 2017-08-02
CA2662480A1 (en) 2008-03-13
BRPI0715869A2 (pt) 2013-07-30
CA2662480C (en) 2016-11-08
ES2616204T3 (es) 2017-06-09
WO2008030505A3 (en) 2008-06-19
EP2913342A1 (en) 2015-09-02
WO2008030505A2 (en) 2008-03-13
IL197148A (en) 2016-06-30
WO2008030505A8 (en) 2009-03-05
EP2380907A1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
ES2530637T3 (es) Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
CR10680A (es) Composiciones de inhibidores de chk1
UA107929C2 (en) Antibodies against cxcr4 for the treatment of hiv infection
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
MA32934B1 (fr) Combinaisons inhibitrices hsp90
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
CO6410314A2 (es) Proteínas de unión a il-17
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
BRPI0905369C8 (pt) composição farmacêutica, uso da composição farmacêutica e kit compartimentado
ES2722824T3 (es) Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CU20140073A7 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p